TY - JOUR
T1 - Risk of Progression to Autoimmune Disease in Severe Drug Eruption
T2 - Risk Factors and the Factor-Guided Stratification
AU - Mizukawa, Yoshiko
AU - Aoyama, Yumi
AU - Takahashi, Hayato
AU - Takahashi, Ryo
AU - Shiohara, Tetsuo
N1 - Funding Information:
The authors thank Michiko Kurosawa (Department of Epidemiology and Environmental Health, Juntendo University School of Medicine, Tokyo, Japan) for excellent suggestions for statistical analyses. This work was supported in part by grants from the Ministry of Education, Culture, Sports, Science and Technology (24390276 to TS) and was supported by Japan Society for the Promotion of Science KAKENHI Grant Number JP 19K08755 (to YM); the Ministry of Health, Labor and Welfare of Japan (to TS); Japanese Research Committee on Severe Cutaneous Adverse Reaction (H26-nanchi(nan)-ippan-081) (to TS); and Health and Labor Sciences Research Grants (Research on Intractable Diseases) from the Ministry of Health , Labor, and Welfare of Japan (to YM and HT). No datasets were generated or analyzed during this study.
Funding Information:
The authors thank Michiko Kurosawa (Department of Epidemiology and Environmental Health, Juntendo University School of Medicine, Tokyo, Japan) for excellent suggestions for statistical analyses. This work was supported in part by grants from the Ministry of Education, Culture, Sports, Science and Technology (24390276 to TS) and was supported by Japan Society for the Promotion of Science KAKENHI Grant Number JP 19K08755 (to YM); the Ministry of Health, Labor and Welfare of Japan (to TS); Japanese Research Committee on Severe Cutaneous Adverse Reaction (H26-nanchi(nan)-ippan-081) (to TS); and Health and Labor Sciences Research Grants (Research on Intractable Diseases) from the Ministry of Health, Labor, and Welfare of Japan (to YM and HT). No datasets were generated or analyzed during this study. Conceptualization: YM, TS; Formal Analysis: YM, YA, HT, RT; Funding Acquisition: YM, TS; Investigation: YM, YA, HT, RT, TS; Resources: YM, HT; Writing - Original Draft Preparation: YM, TS; Writing - Review and Editing: YM, TS
Publisher Copyright:
© 2021 The Authors
PY - 2022/3
Y1 - 2022/3
N2 - The identification of risk factors is key not only to uncover the pathogenesis of autoimmune disease but also to predict progression to autoimmune disease. Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms is likely the best prototypic example for analyzing the sequential events. We conducted a retrospective study of 55 patients with drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms followed up for the possibility of later development of autoimmune disease ∼18 years after resolution. Nine patients progressed to autoimmune sequelae regardless of treatment. The generation of autoantibodies was preceded by 8 years in eight of the nine patients. The combination of increases in lymphocyte counts, severe liver damage, a rebound increase in globulin, persistent reactivations of Epstein‒Barr virus and human herpesvirus-6, and low IL-2 and IL-4 at the acute/subacute phases were significant risk factors for the future development of autoimmune disease. On the basis of these factors, we established a scoring system that can identify high-risk patients. When stratified these patients into three risk categories (low/intermediate/high), occurrence of autoimmune disease was exclusively detected in the high group. Our data represent a scoring system to identify patients at high risk of developing autoimmune disease, although a larger study is required to validate the scoring system.
AB - The identification of risk factors is key not only to uncover the pathogenesis of autoimmune disease but also to predict progression to autoimmune disease. Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms is likely the best prototypic example for analyzing the sequential events. We conducted a retrospective study of 55 patients with drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms followed up for the possibility of later development of autoimmune disease ∼18 years after resolution. Nine patients progressed to autoimmune sequelae regardless of treatment. The generation of autoantibodies was preceded by 8 years in eight of the nine patients. The combination of increases in lymphocyte counts, severe liver damage, a rebound increase in globulin, persistent reactivations of Epstein‒Barr virus and human herpesvirus-6, and low IL-2 and IL-4 at the acute/subacute phases were significant risk factors for the future development of autoimmune disease. On the basis of these factors, we established a scoring system that can identify high-risk patients. When stratified these patients into three risk categories (low/intermediate/high), occurrence of autoimmune disease was exclusively detected in the high group. Our data represent a scoring system to identify patients at high risk of developing autoimmune disease, although a larger study is required to validate the scoring system.
UR - http://www.scopus.com/inward/record.url?scp=85123706347&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123706347&partnerID=8YFLogxK
U2 - 10.1016/j.jid.2021.11.008
DO - 10.1016/j.jid.2021.11.008
M3 - Article
C2 - 34808234
AN - SCOPUS:85123706347
SN - 0022-202X
VL - 142
SP - 960-968.e9
JO - Journal of Investigative Dermatology
JF - Journal of Investigative Dermatology
IS - 3
ER -